IQVIA and the NBA Selected for Abbott’s UNIVANTS of Healthcare Excellence Award

RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life science industry, today announced that it has been recognized along with the National Basketball Association and partners at Harvard, Columbia and BioReference Laboratories for its work in supporting the league with the 2020 NBA Bubble. The Bubble was a closed-campus occupational health program implemented to ensure the smooth operation of the professional basketball league during the COVID-19 pandemic.

The UNIVANTS of Healthcare Excellence awards recognize teams that work together to achieve better health system performance through uniting across disciplines, challenging traditional thought and achieving better outcomes for patients, clinicians and payors.

“Abbott is pleased to recognize IQVIA, the NBA, and all partners associated with the NBA Bubble,” said Alex Carterson, MD, PhD Divisional Vice President, Core Diagnostics Medical Affairs, Abbott. “The NBA Bubble was a novel best practice that successfully maximized the value of clinical laboratory medicine, diagnostics and clinical practice to protect health, advance science and unite communities. On behalf of Abbott, and all program partners of the UNIVANTS of Healthcare Excellence program, we congratulate you on your innovation and commitment to health excellence.”

The NBA Bubble was the first large-scale occupational health operation of its kind to enable a business to resume operations while preventing the spread of COVID-19. IQVIA managed the inflow of daily PCR test results and provided near real-time decision-grade analytics to inform the protocols for the mitigation of COVID-19 infections. The standards set with The NBA Bubble directly informed safety protocols at other large sporting events in the time since, while also improving the broader understanding of the transmission and trajectory of COVID-19.

“We are excited to be honored along with the NBA and partners for the incredible achievement that was the Bubble,” said Christina Mack, Chief Scientific Officer, Real World Solutions, IQVIA. “Every possible measure was taken to ensure safety of the population and proper execution, and much was learned in the process that contributed to public health efforts over and beyond the pandemic. Many thanks to UNIVANTS for recognizing the creativity, innovation and people-first approach of this effort.”

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 87,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.

Contacts

Nick Childs, IQVIA Investor Relations ([email protected])

+1.973.316.3828

Trent Brown, IQVIA Media Relations ([email protected])

+1.919.780.3221